Company Overview
- Website
- nflection.com
- Employees
- 3
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$10B
Recent News & Media
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
- Jul 1, 2025
- theglobeandmail.com
Neurofibromatosis Type 1 Market Set to Witness Significant
- May 15, 2025
- globenewswire.com
Neurofibromatosis Type 2 Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Recursion Pharma, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics
- Mar 24, 2025
- barchart.com
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas
- Mar 19, 2025
- ascopubs.org
Neurofibroma Market Expected to Exhibit a CAGR of 11.5% During 2025-2035, Impelled by Advances in Genetic Research and Precision Medicine
- Feb 6, 2025
- biospace.com
Novel Treatments for Cutaneous Neurofibromas Show Promise
- Jan 23, 2025
- medscape.com
NFlection Therapeutics Industry Tags
Companies Similar to NFlection Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to NFlection Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 59 | Boston, MA | ||
| 10M | 27 | Cambridge, MA | 2010 | |
| 10M | 23 | Waltham, MA | 1999 | |
| 10M | 2 | Boston, MA | ||
| 10M | 46 | Woburn, MA |